JP2020536923A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020536923A5 JP2020536923A5 JP2020520587A JP2020520587A JP2020536923A5 JP 2020536923 A5 JP2020536923 A5 JP 2020536923A5 JP 2020520587 A JP2020520587 A JP 2020520587A JP 2020520587 A JP2020520587 A JP 2020520587A JP 2020536923 A5 JP2020536923 A5 JP 2020536923A5
- Authority
- JP
- Japan
- Prior art keywords
- blinatumomab
- pembrolizumab
- variant
- administered
- subject
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2023164647A JP2024001071A (ja) | 2017-10-13 | 2023-09-27 | びまん性大細胞型ｂ細胞リンパ腫を治療するための組成物及び方法 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762571870P | 2017-10-13 | 2017-10-13 | |
| US62/571,870 | 2017-10-13 | ||
| PCT/US2018/055667 WO2019075366A1 (en) | 2017-10-13 | 2018-10-12 | COMPOSITIONS AND METHODS FOR TREATING DIFFUSED LYMPHOMA WITH LARGE B CELLS |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023164647A Division JP2024001071A (ja) | 2017-10-13 | 2023-09-27 | びまん性大細胞型ｂ細胞リンパ腫を治療するための組成物及び方法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2020536923A JP2020536923A (ja) | 2020-12-17 |
| JP2020536923A5 true JP2020536923A5 (https=) | 2021-11-18 |
Family
ID=64110107
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020520587A Pending JP2020536923A (ja) | 2017-10-13 | 2018-10-12 | びまん性大細胞型ｂ細胞リンパ腫を治療するための組成物及び方法 |
| JP2023164647A Pending JP2024001071A (ja) | 2017-10-13 | 2023-09-27 | びまん性大細胞型ｂ細胞リンパ腫を治療するための組成物及び方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023164647A Pending JP2024001071A (ja) | 2017-10-13 | 2023-09-27 | びまん性大細胞型ｂ細胞リンパ腫を治療するための組成物及び方法 |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US20200262919A1 (https=) |
| EP (1) | EP3694520A1 (https=) |
| JP (2) | JP2020536923A (https=) |
| KR (1) | KR20200068655A (https=) |
| CN (1) | CN111212646A (https=) |
| AU (1) | AU2018347457A1 (https=) |
| BR (1) | BR112020007203A2 (https=) |
| CA (1) | CA3075291A1 (https=) |
| CL (1) | CL2020000973A1 (https=) |
| EA (1) | EA202090565A1 (https=) |
| IL (1) | IL273805A (https=) |
| MX (2) | MX2020003395A (https=) |
| SG (1) | SG11202002374RA (https=) |
| TW (1) | TW201922283A (https=) |
| WO (1) | WO2019075366A1 (https=) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HRP20131167T1 (hr) | 2007-06-18 | 2014-01-03 | Merck Sharp & Dohme B.V. | Antitijela za humani receptor programirane smrti pd-1 |
| WO2021183861A1 (en) * | 2020-03-12 | 2021-09-16 | Amgen Inc. | Method for treatment and prophylaxis of crs in patients comprising a combination of bispecifc antibodies binding to cds x cancer cell and tnfalpha or il-6 inhibitor |
| US20230331844A1 (en) * | 2020-10-12 | 2023-10-19 | Greffex, Inc. | Antibody constructs to target t cell responses to sars-cov protein expressing cells, their design and uses |
| JP2026502330A (ja) * | 2022-11-01 | 2026-01-22 | テネオツー・インコーポレイテッド | 非ホジキンリンパ腫を治療する方法 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| ATE243754T1 (de) | 1987-05-21 | 2003-07-15 | Micromet Ag | Multifunktionelle proteine mit vorbestimmter zielsetzung |
| CZ302070B6 (cs) | 1998-04-21 | 2010-09-29 | Micromet Ag | Jednoretezcový multifunkcní polypeptid, polynukleotid, vektor obsahující tento polynukleotid, bunka transfekovaná tímto polynukleotidem, prostredek obsahující tento polypeptid, polynukleotid nebo vektor a jejich použití a zpusob identifikace aktiváto |
| CA2522586C (en) | 2003-05-31 | 2017-02-21 | Micromet Ag | Pharmaceutical compositions comprising bispecific anti-cd3, anti-cd19 antibody constructs for the treatment of b-cell related disorders |
| WO2008119565A2 (en) | 2007-04-03 | 2008-10-09 | Micromet Ag | Cross-species-specific binding domain |
| HRP20131167T1 (hr) | 2007-06-18 | 2014-01-03 | Merck Sharp & Dohme B.V. | Antitijela za humani receptor programirane smrti pd-1 |
| WO2016019969A1 (en) * | 2014-08-08 | 2016-02-11 | Ludwig-Maximilians-Universität München | Subcutaneously administered bispecific antibodies for use in the treatment of cancer |
| US10751412B2 (en) | 2015-05-29 | 2020-08-25 | Merck Sharp & Dohme Corp. | Combination of a PD-1 antagonist and CPG-C type oligonucleotide for treating cancer |
| EP3316888A1 (en) * | 2015-07-02 | 2018-05-09 | Celgene Corporation | Combination therapy for treatment of hematological cancers and solid tumors |
-
2018
- 2018-10-12 EA EA202090565A patent/EA202090565A1/ru unknown
- 2018-10-12 BR BR112020007203-6A patent/BR112020007203A2/pt unknown
- 2018-10-12 MX MX2020003395A patent/MX2020003395A/es unknown
- 2018-10-12 EP EP18797306.0A patent/EP3694520A1/en not_active Withdrawn
- 2018-10-12 US US16/648,568 patent/US20200262919A1/en not_active Abandoned
- 2018-10-12 JP JP2020520587A patent/JP2020536923A/ja active Pending
- 2018-10-12 WO PCT/US2018/055667 patent/WO2019075366A1/en not_active Ceased
- 2018-10-12 AU AU2018347457A patent/AU2018347457A1/en not_active Abandoned
- 2018-10-12 SG SG11202002374RA patent/SG11202002374RA/en unknown
- 2018-10-12 CA CA3075291A patent/CA3075291A1/en active Pending
- 2018-10-12 KR KR1020207009219A patent/KR20200068655A/ko not_active Ceased
- 2018-10-12 CN CN201880066675.2A patent/CN111212646A/zh active Pending
- 2018-10-15 TW TW107136236A patent/TW201922283A/zh unknown
-
2020
- 2020-04-05 IL IL273805A patent/IL273805A/en unknown
- 2020-04-09 CL CL2020000973A patent/CL2020000973A1/es unknown
- 2020-07-13 MX MX2024001888A patent/MX2024001888A/es unknown
-
2023
- 2023-09-27 JP JP2023164647A patent/JP2024001071A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020536923A5 (https=) | ||
| JP2015187157A5 (https=) | ||
| JP2017503820A5 (https=) | ||
| JP2017226708A5 (https=) | ||
| JP2020002171A5 (https=) | ||
| JP2012193216A5 (https=) | ||
| JP2018193377A5 (https=) | ||
| JP2017149726A5 (https=) | ||
| JP2012518624A5 (https=) | ||
| JP2017048208A5 (https=) | ||
| JP2009545600A5 (https=) | ||
| JP2018506550A5 (https=) | ||
| JP2012067116A5 (https=) | ||
| JP2018505882A5 (https=) | ||
| JP2018507243A5 (https=) | ||
| JP2016515586A5 (https=) | ||
| IL307992A (en) | Parasitic formulations containing isoxazoline and methods for treating blepharitis | |
| JP2006513184A5 (https=) | ||
| JP2012502103A5 (https=) | ||
| JP2017537927A5 (https=) | ||
| JP2015507020A5 (https=) | ||
| JP2006514681A5 (https=) | ||
| JP2010504307A5 (https=) | ||
| RU2006132069A (ru) | Противораковые терапии | |
| JP2018522881A5 (https=) |